China Medical University Hospital (CMUH) Triapin Listing

Inclusion criteria: * Uncontrolled essential hypertension defined by office SBP/DBP \> 140/90 or \> 130/80 mmHg for compelling indications (diabetes mellitus, chronic kidney disease, known CAD or CAD equivalent or 10-year Framingham risk score \> 10%) * Previously untreated, or previously treated with a single antihypertensive therapy at usual dose during the last 4 weeks Exclusion criteria: * Female who are pregnant or breast feeding * Office DBP\> 110mmHg or office SBP \>180mmHg * Hypersensitivity to ramipril, felodipine or to any of the excipients * Bilateral stenosis of the renal arteries, or unilateral stenosis in the single kidney * History of intolerance to any ACE inhibitor * History of significant renal diseases including: serum creatinine \>3.0 mg/dl, or creatinine clearance \<30 ml/min * History of hereditary and/or idiopathic angioedema; or angioedema associated with previous ACEI * Significant cardiovascular diseases, multiple drug allergies, bronchospastic disease or other malignancies requiring current medication * Hepatic disease as indicated by any of the following: Serum Glutamooxaloacetate Transferase (SGOT) or Serum Glutamopyruvate Transferase (SGPT)\>3 x upper limit of normal, or serum bilirubin \> 2 x upper limit of normal * Any other condition or therapy that, in the investigator's opinion, or as indicated in the product(s) label may pose a risk to the patient or interfere with the study objective. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.